Brief: Huadong Medicine Says Unit, Arcutis Biotherapeutics' Drug Gets US FDA Approval
18/12/2023 09:15
Dec 18 (Reuters) - Huadong Medicine Co Ltd 000963.SZ :
* SAYS UNIT AND ARCUTIS BIOTHERAPEUTICS INC' SEBORRHEIC
DERMATITIS
DRUG ZORYVE GETS APPROVAL FROM US FDA
Source text
Further company coverage: 000963.SZ
(Reporting by Hong Kong Newsroom)
((Ethan.Wang@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf